Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

50.85 -2.96 (-5.49%)
Delayed Quote Updated: 1:53 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ nPulse™ Technology to be Featured at the 21st Annual International VT Symposium 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at Canaccord Genuity’s 46th Annual Growth Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences to Host Analyst Event on April 25, 2026
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences Strengthens Executive Leadership Team
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference
From Pulse Biosciences, Inc
Via Business Wire
News headline image
Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.